Detection and early diagnosis of prostate cancer

• US 6,140,049 A
• Filed: 04/29/1998
• Issued: 10/31/2000
• Est. Priority Date: 11/21/1996
• Status: Expired due to Term

• Current Assignee: Serono Genetics Institute S.A. (Merck & Co., Inc.)
• Original Assignee: Genset SA
• Inventors: Bachner, Lucien, Berthon, Philippe
• Primary Examiner(s): Fredman, Jeffrey
• Assistant Examiner(s): SWITZER, JULIET CAROLINE
• Application Number:
  US09/070,106
• Time in Patent Office: 916 Days
• Field of Search: 435/6, 435/91.2, 536/24.32, 536/24.31
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention relates to methods for detecting a predisposition or susceptibility to prostate cancer in an individual using microsatellite markers. These markers are located on chromosomes 1, 2, 4, 5, 11 and 13.

Claims

1. A method for detecting a predisposition or susceptibility to prostate cancer in an individual, said method comprising detecting, in a biological sample from the said individual, alleles of the markers linked to the occurrence of prostate cancer in his family as indicative of the presence of a predisposition or susceptibility to prostate cancer, these markers being selected from the microsatellite markers included in one of the groups of markers consisting of:

D1S235, D1S2678, D1S2785, D1S321, D1S2842 of chromosome 1, D1S252, D1S498, D1S305, D1S484, D1S196of chromosome 1, D2S155, D2S325, D2S2242, D2S2321, D2S317, D2S2319, D2S2382, D2S2249, D2S163, D2S339 of chromosome 2, D4S405, D4S2974, D4S2996, D4S428, D4S2978, D4S3019, D4S1592, D4S398, D4S2987, D4S3004, D4S3018, D4S392, D4S1543 of chromosome 4, D5S2002, D5S2117, D5S393, D5S414, D5S2011, D5S2017, D5S436, D5S2090, D5S2013 of chromosome 5, D11S898, D11S927, D11S908, D11S1345, D11S934, D11S1320 of chromosome 11, D13S1290, D13S1283, D13S1230, D13S1234, D13S265, D13S1300, D13S281 of chromosome 13 and all polymorphic markers localized in the regions situated between the above markers and determining whether said detected alleles are indicative of a predisposition or susceptibility to prostate cancer.

2. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 1 in the region situated between the markers D1S2678 and D1S321.

3. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 1 in the region situated between the markers D1S498 and D1S196.

4. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 2 in the region situated between the markers D2S2319 and D2S163.

5. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 4 in the region situated between the markers D4S2978 and D4S3018.

6. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 5 in the region situated between the markers D5S393 and D5S436.

7. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 11 in the region situated between the markers D11S908 and D11S934.

8. A method according to claim 1, wherein the marker whose allele is detected is localized on chromosome 13 in the region situated between the markers D13S1283 and D13S1300.

9. A method according to claim 1, wherein the presence of said marker is detected by amplification of the region carrying said marker.

10. A method according to claim 9, wherein the amplification is carried out by PCR.